News & Press

Author: okogen

Taking the Sting Out of Pink Eye

Okogen innovates a novel treatment for a common and often serious ophthalmic condition with no approved therapies. Hear the phrase “pink eye” and more than likely you immediately picture red, runny, painful eyes. You might even feel your own eyes

Read More

Okogen Receives $10 Million Series A Funding

Okogen, Inc., a developer of ophthalmic anti-infective drugs, announced $10 million in Series A funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF) to advance the ongoing development of the company’s lead candidate for viral conjunctivitis (commonly known as pink eye), OKG-0301.

Read More

Okogen Inc. Receives Notice of Allowance from USPTO For Treatment of Viral Conjunctivitis With Ranpirnase

Okogen, Inc., a developer of ophthalmic anti-infectives, received a notice of allowance from the United States Patent and Trademark Office for the use of ranpirnase for the treatment of viral conjunctivitis. “The claims granted under 3IPOK1.0002US, in combination with the our existing in-licensed portfolio, further reinforce our strong intellectual property position,” said Brian M. Strem, Ph.D., Chief Executive Officer of Okogen.

Read More